National Health Act 1953 - Determination under section 93 (No. PB 34 of 2005)

Administered by Department of Health, Disability and Ageing

Legislation au F2005L03724 Not in force Legislative Instrument

Legislation content

EXPLANATORY STATEMENT

 

NATIONAL HEALTH ACT 1953

 

DETERMINATION UNDER SECTION 93

 

NO. PB 34 OF 2005

 

 

The purpose of the Australian Pharmaceutical Benefits Scheme (PBS) is to provide timely, reliable and affordable access for the Australian community to necessary and cost-effective medicines.

 

The PBS is regulated by Part VII of the National Health Act 1953 (the Act), which provides for the supply of listed drugs and medicinal preparations as pharmaceutical benefits.

 

“Pharmaceutical benefit is defined under subsection 84(1) of the Act as  a drug or medicinal preparation in relation to which, by virtue of section 85 of the Act, Part VII of the Act applies.

 

Section 93 of the Act provides for the supply of certain pharmaceutical benefit items to medical practitioners as an emergency drug supply.  These drugs are supplied free of charge to patients.

 

Subsection 93(1) of the Act provides that, except as prescribed, a medical practitioner is authorised to supply such pharmaceutical benefits as the Minister determines to persons who are entitled under Part VII of the Act to receive those pharmaceutical benefits.

 

Subsection 93(2) of the Act provides that the Minister may determine the maximum quantity or number of units of a pharmaceutical benefit which may be obtained by a medical practitioner during a specified period and that the medical practitioner shall obtain the pharmaceutical benefit as prescribed.             

 

The determination under section 93 of the Act sets out the conditions under which a medical practitioner is authorised to supply emergency drugs as pharmaceutical benefits.

 

The Schedule to the determination lists the names of the pharmaceutical benefits to which section 93 applies, together with the form (strength type, size etc.) and maximum quantity of those pharmaceutical benefits.

 

The determination made under section 93 of the Act on 16 September 2005 with effect from

1 October 2005 is repealed and substituted with this determination.

 

This determination is remade to give effect, as from 1 December 2005, to changes to the list of drugs and medicinal preparations available as pharmaceutical benefits, as recommended by the Pharmaceutical Benefits Committee.

 


This determination is remade in order to change the name, and description of form and strength, for Benzylpenicillin Sodium powder for injection to remove references to the

10 mL ampoule of Water for Injections – sterilised, supplied as solvent.  This change is a result of the deletion of Water for Injections – sterilised, injection 10 mL, from the list of ready-prepared medicinal preparations available on the Pharmaceutical Benefits Scheme due to discontinuation by the manufacturer.

 

Consultations

 

The Pharmaceutical Benefits Advisory Committee (PBAC) is the independent expert body, established by section 100A of the Act, which makes recommendations to the Minister for Health and Ageing about which drugs and medicinal preparations should be available as pharmaceutical benefits.  Under subsection 101(4) of the Act, a drug or medicinal preparation may not be declared to be a drug or medicinal preparation to which Part VII of the Act applies unless the PBAC has recommended that it be so declared.  When recommending a medicine be listed on the PBS, the PBAC takes into account the medical conditions for which the medicine has been approved for use in Australia, its clinical effectiveness, safety and cost-effectiveness compared with other treatments.

 

The determination gives effect to recommendations made by the PBAC.  PBAC members are selected from consumers, health economists, practising community pharmacists, general practitioners, clinical pharmacologists and specialists, with at least one member selected from each of those interests or professions.  Remaining members are persons whom the Minister is satisfied have qualifications and experience in a field relevant to the functions of the PBAC, and that would enable them to contribute meaningfully to the deliberations of the PBAC.

 

Details of the determination are set out in the Attachment.

 

This determination is a legislative instrument for the purposes of the Legislative Instruments Act 2003.

 

The determination was made on 23 November 2005 and commenced on 1 December 2005.


ATTACHMENT

 

Paragraph 1 provides that this determination commences on 1 December 2005.

 

Paragraph 2 provides that the determination under section 93 of the National Health Act 1953 (the Act) made on 16 September 2005 is repealed.

 

Paragraph 3 provides that the Schedule to the determination lists those pharmaceutical benefits to which section 93 applies (emergency supply drugs).

 

Paragraph 4 provides that where a medical practitioner has obtained drugs under section 93 of the Act, that medical practitioner, or a locum acting on that medical practitioner’s behalf, may supply those drugs.

 

Paragraph 5 provides that the medical practitioner may not obtain more than the maximum quantity or number of units of a drug in any one month, the maximum quantity or number of units being specified in the Schedule to this determination.

 

Paragraph 6 provides that, if the medical practitioner has obtained a quantity of drugs under section 93 of the Act, and is in possession of a quantity that is equal to or more than the maximum quantity of that drug (as specified in the Schedule), that medical practitioner may not obtain a further quantity of that drug.

 

The Schedule to the determination lists the names of the pharmaceutical benefits to which section 93 applies, together with the form (strength type, size etc.) and maximum quantity of those pharmaceutical benefits.

 

Overview

The National Health Act 1953, enacted by the Australian Parliament, serves to regulate the Australian Pharmaceutical Benefits Scheme (PBS), which aims to ensure that the Australian community has timely, reliable, and affordable access to necessary and cost-effective medicines. The PBS is overseen by Part VII of the Act, which allows for the supply of listed drugs and medicinal preparations as pharmaceutical benefits. Section 93 of the Act authorises the Minister for Health to determine the supply of certain pharmaceutical benefits to medical practitioners for emergency use, which are provided free of charge to patients. This legislative instrument was introduced to address the need for a structured and regulated system to ensure the availability and affordability of essential medications across the country. The policy objective is to maintain a cost-effective and accessible healthcare system by providing necessary medications through the PBS.

Scope and Application

The Australian Pharmaceutical Benefits Scheme (PBS), governed under Part VII of the National Health Act 1953, is intended to ensure that Australians have reliable and affordable access to necessary and cost-effective medicines. This scheme allows medical practitioners to supply certain pharmaceutical benefits to patients free of charge in emergency situations, as authorised by the Minister under section 93 of the Act. The Act applies to medical practitioners who can supply these emergency drugs to eligible patients who are entitled to receive these pharmaceutical benefits under Part VII of the Act. The supply of these benefits is subject to specific conditions, including a limit on the maximum quantity or number of units of a pharmaceutical benefit that can be obtained by a medical practitioner during a specified period, as determined by the Minister. The application of this Act extends across the Commonwealth of Australia, with the Pharmaceutical Benefits Advisory Committee (PBAC) making recommendations to the Minister regarding which drugs and medicinal preparations should be included as pharmaceutical benefits. These recommendations are based on the clinical effectiveness, safety, and cost-effectiveness of the medicines relative to other treatments. The determination under section 93 of the Act is remade to reflect changes in the list of available drugs and medicinal preparations, ensuring that the scheme remains up-to-date and effective.

Key Provisions

The determination under section 93 of the National Health Act 1953, effective from 1 December 2005, establishes the framework for medical practitioners to supply certain pharmaceutical benefits in emergency situations. Specifically, section 93(1) authorises medical practitioners to provide specified pharmaceutical benefits to eligible patients free of charge, as determined by the Minister for Health and Ageing. This authorisation is contingent on the medical practitioner being the one who originally obtained the pharmaceutical benefit or a locum acting on their behalf. The maximum quantity of any particular pharmaceutical benefit that can be obtained by a medical practitioner within a given period is also specified in the Schedule to this determination, as outlined in section 93(2). Under this Act, medical practitioners have clear obligations to adhere to the prescribed conditions for obtaining and supplying emergency pharmaceutical benefits. These obligations include ensuring that the quantity of pharmaceutical benefits obtained does not exceed the specified maximum, as detailed in the Schedule. Additionally, the medical practitioner must only supply drugs obtained under section 93 to patients who are entitled to receive these benefits under Part VII of the Act. The Schedule provides specific details on the form and maximum quantity for each listed pharmaceutical benefit, ensuring transparency and accountability in the emergency drug supply process. Any breach of the provisions set out in this determination may result in both civil and criminal consequences. Although the explanatory statement does not specify the exact penalties, breaches of the National Health Act 1953 can generally lead to substantial fines and, in severe cases, imprisonment. The precise penalties would depend on the nature and severity of the breach, as well as any relevant case law and sentencing guidelines. The overarching aim is to ensure that the supply of emergency pharmaceutical benefits remains within the bounds set by the Act, thereby maintaining the integrity and effectiveness of the Australian Pharmaceutical Benefits Scheme.

Legal classification tags

Area of Law
Health Law
Pharmaceutical Law
Instrument
Determination
Concepts
Definitions & Interpretation
Licensing & Registration
Reporting & Disclosure Obligations

Interactions

Authorises

All Versions

Sourced from the Federal Register of Legislation at 26 August 2026. For the latest information on Australian Government law please go to https://www.legislation.gov.au.